Erector Spinae Plane BlockNCT06377605
The Efficacy of Thoracic Erector Spinae Plane Block For Perioperative Analgesia in Laparoscopic Bariatric Surgery for Super Obese Patients.
A study testing ESPB, local anaesthetic infiltration and midazolam and lidocaine in people with Erector Spinae Plane Block and Super Obese Patients, run by Amany Ahmed Eissa at 1 site in Egypt.
Trial summary
The epidemic of overweight and obesity presents a major challenge to chronic disease prevention and health across the life course around the world. [1] Bariatric surgery has proved to be an efficient intervention in the management of obesity. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Erector Spinae Plane Block, Super Obese Patients, Bariatric Surgery
- What is being tested?
- ESPB, local anaesthetic infiltration and midazolam and lidocaine
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 10 Mar 2024to 15 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patient age >18 <60
- Super Obese patients ; Body mass index(BMI) > 50 kg/m2
- Both sexes
- American Society of Anesthesiologists(ASA) physical status classes II and III
- Patients scheduled for laparoscopic bariatric surgery i.e. sleeve gastrectomy and/or Roux-en-Y gastric bypass (RYGB)surgeries
Who cannot join
- • Refusal of regional block
- Patients with neurological, psychological disorders or those lacking cooperation
- Patients scheduled for concomitant laparoscopic cholecystectomy or paraumbilical hernia repair or those with history of previous bariatric surgery or obstructive sleep apnea
- Patients with anatomic abnormalities at site of injection, skin lesions or wounds at site of proposed needle insertion.
- Patients with bleeding disorders defined as (INR >1.4) and/ or (platelet count <100,000/µL)
- Patients with hepatic disease e.g. liver cell failure or hepatic malignancy or hepatic enlargement.
- Patients who are allergic to amide local anesthetics.
- Cases converted to open surgery will also be excluded from the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Efficacy of Thoracic Erector Spinae Plane Block For Perioperative Analgesia in Laparoscopic Bariatric Surgery for Super Obese Patients: Randomized Controlled Trial
The epidemic of overweight and obesity presents a major challenge to chronic disease prevention and health across the life course around the world. [1] Bariatric surgery has proved to be an efficient intervention in the management of obesity. As a result, the number of post-bariatric surgery patients in the population is growing [2].
Postoperative analgesia presents various challenges in vulnerable patient groups suffering from obesity. With the high potential risk of respiratory depression and postoperative pulmonary complications associated with opioid use, such as atelectasis and pneumonia, the availability of other pain management modalities is essential [14].
Read more
Ultrasound-guided erector spinae plane block (ESPB) is a regional anesthesia technique where local anesthetic agent is injected deep to the erector spinae muscle to fascial plane and allowed to diffuse caudally and cranially. It is supposed to provide both visceral and somatic abdominal analgesia [3].
ESPB is effective, easy to perform, and can be performed in a short time. [4] It has been shown efficacy in different conditions such as thoracic surgery, trauma, cardiac surgery, breast surgery, and abdominal surgery [5]. However, the main concern with the ESPB block is feasibility together with the potency of the block in challenging populations, such as patients suffering from obesity.
Peripheral nerve blocks in the obese may pose challenges, like difficulties in proper patient positioning and landmark identification. However, Ultrasound guidance may help overcome many difficulties in regional techniques. But as expected, targets are more deeply situated in obese patients and the ultrasound beams are attenuated as they travel a greater distance through tissue layers. Additionally, when crossing a tissue boundary, a portion is reflected back to the transducer creating artifacts like speckling and clutter which are particular problems in the obese patient. [15] Few studies examined the use of ESPB in bariatric surgery [3,6,7], all indicating potential benefits of the technique in terms of opioid sparing and pain control. To date, the efficacy of ESPB has not been examined in superobese patient.
So we aim to compare the perioperative analgesic effect of bilateral ultrasound-guided ESPB with controls, Local bupivacaine infiltration to the trocar sites, in super obese patients undergoing bariatric surgery We hypothesis that ESBP provides good applicable modality of perioperative analgesia for superobese patients undergoing bariatric surgeries.
Read the detailed description
Following approval from Ethics and Research Committee of Anaesthesia Department, Faculty of Medicine, Cairo University; 60 patients fulfilling inclusion criteria will be included in this randomized prospective comparative trial.
A.preoperative:
History will be taken from all patients. Age and then American Society Anaesthesiologists' (ASA) score will be recorded.
Preoperatively patients' laboratory investigations as complete blood picture, coagulation profile, liver and renal functions will be recorded. General examination will be carried out with examination of the back to exclude infection at the injection site and anatomical deformities.
Baseline vital signs will be recorded including non-invasive measurement of systolic, mean, diastolic arterial pressures, and HR and oxygen saturation. After inserting an intravenous (IV) access, the patient will be pre-medicated with metoclopramide in a dose 0.1-0.2 mg/kg.
Patient will be randomly assigned into 1 of 2 groups according to the intervention used whether:
- Group A (30 patients): Erector Spinae block .
- Group B (30 patients): local anaesthetic infiltration. Upon arrival to O.R; perioperative monitoring including continuous Electro Cardio Gram (GE-Datex Ohmeda 5 leads ECG cable), pulse oximetry (GE- Datex Ohmeda finger SpO2 sensor), non-invasive arterial blood pressure (GE-Datex Ohmeda NIBP cuff) will be applied.
In group A, block will be performed by the primary investigator the the block will be performed preoperatively with 1mg midazolam administration intravenous , and 5 cm lidocaine 1% infiltration at each side prior to the block .
the patient will be placed in the lateral or sitting position . Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound . It will be sagittally placed against the target vertebral level ( T7 transverse process ) [8] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml normal saline to confirm the correct needle tip position. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) [16] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected , the distribution will be better.
B.intraoperative:
Then, general anaesthesia will be induced in both groups . 1-2 μg/kg fentanyl based on lean body weight [3] with maximum dose of 200 μg and 2 mg/kg propofol will be given based on total body weight [3]. Tracheal intubation will be facilitated with 0.5 mg/kg atracurium based on ideal body weight [10].
In Group (B) Control group : the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
For both groups, Anaesthesia will be maintained using isoflurane in oxygen and air. Additional doses of 0.1 mg/kg atracurium will be administrated every 30 minutes. The surgical intervention will be then allowed 20 minutes after finishing the block procedure in group (A).
Pressure control volume guarantee ventilation will be adjusted to maintain normocapnia. Anesthesia will be maintained by using 1-1.5% isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes.
All participants will be given 1 gram of intravenous paracetamol with maximum dose of 4 gm every 24 hour Failed block ( increase in HR and mean arterial blood pressure (MABP)>20% from base line with skin incision) will be treated by 1ug /kg of fentanyl as top-up doses and increasing isoflurane concentration in case of inadequate response to fentanyl.
20 minute before the end of the surgery ketorolac 0.5mg/kg diluted in 100 ml of saline will be given intravenously After skin closure, inhalational anesthesia will be discontinued and reversal of muscle relaxation with atropine (0.02 mg/Kg) and neostigmine (0.05 mg/Kg) will be administered intravenous after return of patient's spontaneous breathing. Patients will then be transferred to post anesthesia care unit (PACU) for 60 min to complete recovery and monitoring.
At any time hypotension (defined as a decrease in mean arterial pressure (MAP) >20% from baseline value or systolic arterial pressure (SAP <100 mmHg) will be treated with 5 mg IV bolus ephedrine and repeated every 3 minutes until the hypotension resolved. Bradycardia (defined as a HR <40 beats per minute ) will be treated with atropine 0.5 mg IV.[11]
C.postoperative:
In the PACU; VAS will be assessed 15 min after extubation and when the score exceeds 3/10, rescue analgesia in the form of nalbuphine 0.1 mg/Kg with maximum dose of 30 mg every 24 hours will be given. Another dose of nalbuphine 0.1 mg/kg can be given in the PACU if the score still more than 3 after 30 min of the 1st dose.
After discharging from the PACU, the analgesic plan will be intravenous paracetamol one gram every 8 hours , ketorolac 0.5mg/kg/ 6 hours if VAS score > 3 and nalbuphine as second rescue analgesia 0.1 mg/kg /8 hours as long as the pain score is more than 3\10 ( reassessment to be done after 30 mins of administration of first rescue analgesia ) .
- Measurement tools
- Patients characteristics including patient's age in years, weight in kilograms,BMI, gender, type of surgery.
- All hemodynamic parameters as blood pressure using non-invasive measurement, heart rate, oxygen saturation will be recorded at baseline , 5 mins after intubation ,every 10 min till the end of the surgery , immediately after extubation , 5 min after extubation , and every 10 mins in PACU for 30 min till the discharge of the patient .
- Failed blocks will be documented (patient requirement of consecutive rescue analgesia).
- the patients will be evaluated regarding the time to first demand to rescue analgesia postoperatively.
- The pain will be assessed by the VAS score, It will be performed in the immediate post-operative period every 30 min for the first hour , 2 h, 4 h, 8h, 12h and 24 h. Breakthrough pain will be defined as VAS >3 at rest.
- Pain will be classified as mild (VAS 1-3), moderate (VAS 4-6), and severe (VAS 7-10) .
- Postoperative regular analgesia will be prescribed for all patients in the form of paracetamol every 8 hours. Rescue analgesia will be administered, if VAS is >3 at any time with IV ketorolac 0.5 mg/kg diluted in 100 ml normal saline and administered slowly every 6 hours .
Reassessment of VAS score will be done and if VAS is still > 3 the second rescue analgesic planned will be IV nalbuphine 0.1 mg/kg every 8 hours .
- The time interval between the first and the second rescue analgesia will be 30 minutes if VAS score remains persistently >3 .
- Time at which the patient start to ambulate in both groups will be recorded [12]
- PONV in first 24hr will be monitored and documented if occurred.
- complications such as hematoma at the site of injection and local anesthetic toxicity will be documented .
- Quality of recovery questionnaire.QoR15.
VI. Study outcomes
- Primary outcome Total opioid consumption (morphine equivalent dose) in both groups in 24hr postoperative (including Intraoperative fentanyl , and postoperative nalluphine).
- Secondary outcome(s)
- VAS score during first 24 hour postoperative
- Failure rate in performing the block
- Patient demographic data (age ,sex ,ASA classification ,BMI and type of surgery).
- Postoperative nausea and vomiting in first 24 hours.
- Time at which the patient start to ambulate in both groups
- Haemodynamic parameters (heartrate,Blood pressure) recorded intraoperative ,immediately postoperatively and in PAICU.
- Incidence of complications related to the block as infection or hematoma at the site of injection , local anaesthetic toxicity or pneumothorax .
- Time for first rescue analgesia in both groups.
- Quality of recovery questionnaire (QoR15) after 24hr from the end of the surgery
- Being tested
- ESPB, local anaesthetic infiltration, midazolam and lidocaine, Bupivacain
- Keywords
- super obese, ESPB, bariatric
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ESPBProcedure or surgery
the target vertebral level ( T7 transverse process ) [8] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) [16] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected ,
local anaesthetic infiltrationProcedure or surgery
the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
midazolam and lidocaineDrug
midazolam administration intravenous , and 5 cm lidocaine 1% infiltration
BupivacainDrug
bupivacaine infiltration
| Study group | Role | What they receive |
|---|---|---|
| Erector Spinae block . | Active comparator | the block will be performed preoperatively with 1mg midazolam administration intravenous , and 5 cm lidocaine 1% infiltration at each side prior to the block .
the patient will be placed in the lateral or sitting position . The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) [16] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected , the distribution will be better. Receives: Procedure: ESPB; Drug: midazolam and lidocaine |
| local anaesthetic infiltration | Active comparator | : the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation. Receives: Procedure: local anaesthetic infiltration; Drug: Bupivacain |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total opioid consumption
(morphine equivalent dose) in both groups in 24hr postoperative (including Intraoperative fentanyl , and postoperative nalluphine).
Measured: 24 hours
Secondary outcomes (1)
VAS score during first 24 hour postoperative
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2024
- Study start10 Mar 2024
- Primary completion30 May 2025
- Study completion15 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Erector Spinae Plane BlockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized controlled trial- single blinded
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amany Ahmed Eissa
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Amany Ahmed Eissa, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06377605
- Sponsor's protocol ID
- MD-15-2024
- Status last verified
- Nov 2025
- First submitted
- 17 Apr 2024
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy of Thoracic Erector Spinae Plane Block For Perioperative Analgesia in Laparoscopic Bariatric Surgery for Super Obese Patients: Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06377605
- Acronym / sponsor ID
- MD-15-2024
- Keywords
- super obese, ESPB, bariatric
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Amany Ahmed EissaUniversity, hospital or other
- Study start
- 10 Mar 2024 (actual)
- Primary completion
- 30 May 2025 (actual)
- Study completion
- 15 Jun 2025 (actual)
- First posted
- 22 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The epidemic of overweight and obesity presents a major challenge to chronic disease prevention and health across the life course around the world. [1] Bariatric surgery has proved to be an efficient intervention in the management of obesity. As a result, the number of post-bariatric surgery patients in the population is growing [2].
Postoperative analgesia presents various challenges in vulnerable patient groups suffering from obesity. With the high potential risk of respiratory depression and postoperative pulmonary complications associated with opioid use, such as atelectasis and pneumonia, the availability of other pain management modalities is essential [14].
Ultrasound-guided erector spinae plane block (ESPB) is a regional anesthesia technique where local anesthetic agent is injected deep to the erector spinae muscle to fascial plane and allowed to diffuse caudally and cranially. It is supposed to provide both visceral and somatic abdominal analgesia [3].
ESPB is effective, easy to perform, and can be performed in a short time. [4] It has been shown efficacy in different conditions such as thoracic surgery, trauma, cardiac surgery, breast surgery, and abdominal surgery [5]. However, the main concern with the ESPB block is feasibility together with the potency of the block in challenging populations, such as patients suffering from obesity.
Peripheral nerve blocks in the obese may pose challenges, like difficulties in proper patient positioning and landmark identification. However, Ultrasound guidance may help overcome many difficulties in regional techniques. But as expected, targets are more deeply situated in obese patients and the ultrasound beams are attenuated as they travel a greater distance through tissue layers. Additionally, when crossing a tissue boundary, a portion is reflected back to the transducer creating artifacts like speckling and clutter which are particular problems in the obese patient. [15] Few studies examined the use of ESPB in bariatric surgery [3,6,7], all indicating potential benefits of the technique in terms of opioid sparing and pain control. To date, the efficacy of ESPB has not been examined in superobese patient.
So we aim to compare the perioperative analgesic effect of bilateral ultrasound-guided ESPB with controls, Local bupivacaine infiltration to the trocar sites, in super obese patients undergoing bariatric surgery We hypothesis that ESBP provides good applicable modality of perioperative analgesia for superobese patients undergoing bariatric surgeries.
Detailed description
Following approval from Ethics and Research Committee of Anaesthesia Department, Faculty of Medicine, Cairo University; 60 patients fulfilling inclusion criteria will be included in this randomized prospective comparative trial.
A.preoperative:
History will be taken from all patients. Age and then American Society Anaesthesiologists' (ASA) score will be recorded.
Preoperatively patients' laboratory investigations as complete blood picture, coagulation profile, liver and renal functions will be recorded. General examination will be carried out with examination of the back to exclude infection at the injection site and anatomical deformities.
Baseline vital signs will be recorded including non-invasive measurement of systolic, mean, diastolic arterial pressures, and HR and oxygen saturation. After inserting an intravenous (IV) access, the patient will be pre-medicated with metoclopramide in a dose 0.1-0.2 mg/kg.
Patient will be randomly assigned into 1 of 2 groups according to the intervention used whether:
- Group A (30 patients): Erector Spinae block .
- Group B (30 patients): local anaesthetic infiltration. Upon arrival to O.R; perioperative monitoring including continuous Electro Cardio Gram (GE-Datex Ohmeda 5 leads ECG cable), pulse oximetry (GE- Datex Ohmeda finger SpO2 sensor), non-invasive arterial blood pressure (GE-Datex Ohmeda NIBP cuff) will be applied.
In group A, block will be performed by the primary investigator the the block will be performed preoperatively with 1mg midazolam administration intravenous , and 5 cm lidocaine 1% infiltration at each side prior to the block .
the patient will be placed in the lateral or sitting position . Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound . It will be sagittally placed against the target vertebral level ( T7 transverse process ) [8] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml normal saline to confirm the correct needle tip position. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) [16] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected , the distribution will be better.
B.intraoperative:
Then, general anaesthesia will be induced in both groups . 1-2 μg/kg fentanyl based on lean body weight [3] with maximum dose of 200 μg and 2 mg/kg propofol will be given based on total body weight [3]. Tracheal intubation will be facilitated with 0.5 mg/kg atracurium based on ideal body weight [10].
In Group (B) Control group : the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
For both groups, Anaesthesia will be maintained using isoflurane in oxygen and air. Additional doses of 0.1 mg/kg atracurium will be administrated every 30 minutes. The surgical intervention will be then allowed 20 minutes after finishing the block procedure in group (A).
Pressure control volume guarantee ventilation will be adjusted to maintain normocapnia. Anesthesia will be maintained by using 1-1.5% isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes.
All participants will be given 1 gram of intravenous paracetamol with maximum dose of 4 gm every 24 hour Failed block ( increase in HR and mean arterial blood pressure (MABP)>20% from base line with skin incision) will be treated by 1ug /kg of fentanyl as top-up doses and increasing isoflurane concentration in case of inadequate response to fentanyl.
20 minute before the end of the surgery ketorolac 0.5mg/kg diluted in 100 ml of saline will be given intravenously After skin closure, inhalational anesthesia will be discontinued and reversal of muscle relaxation with atropine (0.02 mg/Kg) and neostigmine (0.05 mg/Kg) will be administered intravenous after return of patient's spontaneous breathing. Patients will then be transferred to post anesthesia care unit (PACU) for 60 min to complete recovery and monitoring.
At any time hypotension (defined as a decrease in mean arterial pressure (MAP) >20% from baseline value or systolic arterial pressure (SAP <100 mmHg) will be treated with 5 mg IV bolus ephedrine and repeated every 3 minutes until the hypotension resolved. Bradycardia (defined as a HR <40 beats per minute ) will be treated with atropine 0.5 mg IV.[11]
C.postoperative:
In the PACU; VAS will be assessed 15 min after extubation and when the score exceeds 3/10, rescue analgesia in the form of nalbuphine 0.1 mg/Kg with maximum dose of 30 mg every 24 hours will be given. Another dose of nalbuphine 0.1 mg/kg can be given in the PACU if the score still more than 3 after 30 min of the 1st dose.
After discharging from the PACU, the analgesic plan will be intravenous paracetamol one gram every 8 hours , ketorolac 0.5mg/kg/ 6 hours if VAS score > 3 and nalbuphine as second rescue analgesia 0.1 mg/kg /8 hours as long as the pain score is more than 3\10 ( reassessment to be done after 30 mins of administration of first rescue analgesia ) .
- Measurement tools
- Patients characteristics including patient's age in years, weight in kilograms,BMI, gender, type of surgery.
- All hemodynamic parameters as blood pressure using non-invasive measurement, heart rate, oxygen saturation will be recorded at baseline , 5 mins after intubation ,every 10 min till the end of the surgery , immediately after extubation , 5 min after extubation , and every 10 mins in PACU for 30 min till the discharge of the patient .
- Failed blocks will be documented (patient requirement of consecutive rescue analgesia).
- the patients will be evaluated regarding the time to first demand to rescue analgesia postoperatively.
- The pain will be assessed by the VAS score, It will be performed in the immediate post-operative period every 30 min for the first hour , 2 h, 4 h, 8h, 12h and 24 h. Breakthrough pain will be defined as VAS >3 at rest.
- Pain will be classified as mild (VAS 1-3), moderate (VAS 4-6), and severe (VAS 7-10) .
- Postoperative regular analgesia will be prescribed for all patients in the form of paracetamol every 8 hours. Rescue analgesia will be administered, if VAS is >3 at any time with IV ketorolac 0.5 mg/kg diluted in 100 ml normal saline and administered slowly every 6 hours .
Reassessment of VAS score will be done and if VAS is still > 3 the second rescue analgesic planned will be IV nalbuphine 0.1 mg/kg every 8 hours .
- The time interval between the first and the second rescue analgesia will be 30 minutes if VAS score remains persistently >3 .
- Time at which the patient start to ambulate in both groups will be recorded [12]
- PONV in first 24hr will be monitored and documented if occurred.
- complications such as hematoma at the site of injection and local anesthetic toxicity will be documented .
- Quality of recovery questionnaire.QoR15.
VI. Study outcomes
- Primary outcome Total opioid consumption (morphine equivalent dose) in both groups in 24hr postoperative (including Intraoperative fentanyl , and postoperative nalluphine).
- Secondary outcome(s)
- VAS score during first 24 hour postoperative
- Failure rate in performing the block
- Patient demographic data (age ,sex ,ASA classification ,BMI and type of surgery).
- Postoperative nausea and vomiting in first 24 hours.
- Time at which the patient start to ambulate in both groups
- Haemodynamic parameters (heartrate,Blood pressure) recorded intraoperative ,immediately postoperatively and in PAICU.
- Incidence of complications related to the block as infection or hematoma at the site of injection , local anaesthetic toxicity or pneumothorax .
- Time for first rescue analgesia in both groups.
- Quality of recovery questionnaire (QoR15) after 24hr from the end of the surgery
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- randomized controlled trial- single blinded
| Arm | Type | Receives |
|---|---|---|
| Erector Spinae block . | Active comparator | Procedure: ESPB, Drug: midazolam and lidocainethe block will be performed preoperatively with 1mg midazolam administration intravenous , and 5 cm lidocaine 1% infiltration at each side prior to the block . the patient will be placed in the lateral or sitting position . The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) [16] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected , the distribution will be better. |
| local anaesthetic infiltration | Active comparator | Procedure: local anaesthetic infiltration, Drug: Bupivacain: the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Patient age >18 <60
Key exclusion criteria (8 listed)
- • Refusal of regional block
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ESPBthe target vertebral level ( T7 transverse process ) [8] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) [16] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected , | Procedure or surgery | Erector Spinae block . |
| local anaesthetic infiltrationthe participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation. | Procedure or surgery | local anaesthetic infiltration |
| midazolam and lidocainemidazolam administration intravenous , and 5 cm lidocaine 1% infiltration | Drug | Erector Spinae block . |
| Bupivacainbupivacaine infiltration | Drug | local anaesthetic infiltration |
Primary outcome
Total opioid consumption
Time frame: 24 hours
(morphine equivalent dose) in both groups in 24hr postoperative (including Intraoperative fentanyl , and postoperative nalluphine).
1 secondary outcome
VAS score during first 24 hour postoperative
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Erector Spinae Plane Block
RecruitingPhase 4
PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
Hip Disease, Hip Dysplasia
Not yet recruiting
Adding Different Doses of Dexmedetomidine to Bupivecaine in Erector Spinae Plane Block
Postoperative Pain in Lumbar Spine Surgery
Recruiting
Lumbar Paravertebral Block vs Erector Spinae Plane Block in Elderly Patients Undergoing Lumbar Spine Surgery
Spine Disease
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
Not yet recruiting
Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Femur Neck Fracture, Hip Fractures
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ESPB, local anaesthetic infiltration and midazolam and lidocaine in people with Erector Spinae Plane Block and Super Obese Patients, run by Amany Ahmed Eissa at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total opioid consumption (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025; AzTrials last refreshed its copy on 7 Nov 2026.